Pliant Therapeutics Inc’s recent filing unveils that its President and CEO Coulie Bernard unloaded Company’s shares for reported $0.59 million on Jan 17 ’25. In the deal valued at $11.20 per share,52,419 shares were sold. As a result of this transaction, Coulie Bernard now holds 430,517 shares worth roughly $1.12 million.
Then, Cummings Keith Lamont sold 20,148 shares, generating $225,680 in total proceeds. Upon selling the shares at $11.20, the Chief Financial Officer now owns 262,608 shares.
Before that, Hull Hans sold 15,936 shares. Pliant Therapeutics Inc shares valued at $178,501 were divested by the Chief Business Officer at a price of $11.20 per share. As a result of the transaction, Hull Hans now holds 211,558 shares, worth roughly $0.55 million.
Wells Fargo downgraded its Pliant Therapeutics Inc [PLRX] rating to an Equal weight from a an Overweight in a research note published on February 10, 2025; the price target was decreased to $4 from $41. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who decreased its forecast for the stock in early February from “an Outperform” to “a Sector perform”. Oppenheimer also remained covering PLRX and has decreased its forecast on February 10, 2025 with a “Perform” recommendation from previously “an Outperform” rating. JP Morgan revised its rating on February 10, 2025. It rated PLRX as “a Neutral” which previously was an “an Overweight”.
Price Performance Review of PLRX
On Tuesday, Pliant Therapeutics Inc [NASDAQ:PLRX] saw its stock fall -15.15% to $2.61. Over the last five days, the stock has lost -77.09%. Pliant Therapeutics Inc shares have fallen nearly -80.22% since the year began. Nevertheless, the stocks have fallen -84.01% over the past one year. While a 52-week high of $18.00 was reached on 01/03/25, a 52-week low of $2.82 was recorded on 02/11/25. SMA at 50 days reached $12.32, while 200 days put it at $12.67.
Levels Of Support And Resistance For PLRX Stock
The 24-hour chart illustrates a support level at 2.45, which if violated will result in even more drops to 2.29. On the upside, there is a resistance level at 2.92. A further resistance level may holdings at 3.23. The Relative Strength Index (RSI) on the 14-day chart is 17.50, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -5.27, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 99.95%. Stochastics %K at 4.41% indicates the stock is a buying.
How much short interest is there in Pliant Therapeutics Inc?
A steep rise in short interest was recorded in Pliant Therapeutics Inc stocks on 2025-01-31, growing by 66842.0 shares to a total of 7.23 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-31 was 7.17 million shares. There was a rise of 0.92%, which implies that there is a positive sentiment for the stock.
